DALY and QALY

Last updated: November 01, 2022

DALY and QALY

PED STEP2

PED STEP2

Eating disorders: Pathology review
Psychiatric emergencies: Pathology review
Attributable risk (AR)
Bias in interpreting results of clinical studies
Bias in performing clinical studies
Clinical trials
Confounding
DALY and QALY
Direct standardization
Disease causality
Incidence and prevalence
Indirect standardization
Interaction
Mortality rates and case-fatality
Odds ratio
Positive and negative predictive value
Prevention
Relative and absolute risk
Selection bias
Sensitivity and specificity
Study designs
Test precision and accuracy
Acyanotic congenital heart defects: Pathology review
Adrenal masses: Pathology review
Bacterial and viral skin infections: Pathology review
Bone tumors: Pathology review
Coagulation disorders: Pathology review
Congenital neurological disorders: Pathology review
Cyanotic congenital heart defects: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Headaches: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Leukemias: Pathology review
Lymphomas: Pathology review
Macrocytic anemia: Pathology review
Microcytic anemia: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Nasal, oral and pharyngeal diseases: Pathology review
Nephritic syndromes: Pathology review
Nephrotic syndromes: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Pediatric brain tumors: Pathology review
Pediatric musculoskeletal disorders: Pathology review
Platelet disorders: Pathology review
Renal and urinary tract masses: Pathology review
Seizures: Pathology review
Viral exanthems of childhood: Pathology review
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Drug-receptor interactions
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug metabolism
Cystic fibrosis: Pathology review
Diabetes mellitus: Pathology review
HIV and AIDS: Pathology review
Obstructive lung diseases: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Antidiuretic hormone
Body fluid compartments
Movement of water between body compartments
Sodium homeostasis
Acid-base disturbances: Pathology review
Diabetes insipidus and SIADH: Pathology review
Electrolyte disturbances: Pathology review
Renal failure: Pathology review
Growth hormone and somatostatin
Childhood and early-onset psychological disorders: Pathology review
Breastfeeding
Central nervous system infections: Pathology review
Congenital TORCH infections: Pathology review
Jaundice: Pathology review
Respiratory distress syndrome: Pathology review
Ectoderm
Endoderm
Human development days 1-4
Human development days 4-7
Human development week 2
Human development week 3
Mesoderm
Cell cycle
DNA damage and repair
DNA mutations
DNA replication
DNA structure
Epigenetics
Gene regulation
Mitosis and meiosis
Nuclear structure
Transcription of DNA
Translation of mRNA
Hardy-Weinberg equilibrium
Independent assortment of genes and linkage
Inheritance patterns
Mendelian genetics and punnett squares
Autosomal trisomies: Pathology review
Disorders of sex chromosomes: Pathology review
Miscellaneous genetic disorders: Pathology review
Baroreceptors
Cardiac preload
Chemoreceptors
Renin-angiotensin-aldosterone system
Adrenal insufficiency: Pathology review
Congenital gastrointestinal disorders: Pathology review
Environmental and chemical toxicities: Pathology review
Gastrointestinal bleeding: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Inflammatory bowel disease: Pathology review
Medication overdoses and toxicities: Pathology review
Pneumonia: Pathology review
Shock: Pathology review
Supraventricular arrhythmias: Pathology review
Traumatic brain injury: Pathology review
Ventricular arrhythmias: Pathology review
Introduction to pharmacology
Androgens and antiandrogens
Estrogens and antiestrogens
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Antihistamines for allergies
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Glucocorticoids
Azoles
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Developmental milestones: Clinical
Disruptive, impulse-control and conduct disorders: Clinical
Eating disorders: Clinical
Elimination disorders: Clinical
Neurodevelopmental disorders: Clinical
Child abuse: Clinical
BRUE, ALTE, and SIDS: Clinical
Congenital heart defects: Clinical
Fever of unknown origin: Clinical
Kawasaki disease: Clinical
Pediatric bone and joint infections: Clinical
Pediatric constipation: Clinical
Pediatric ear, nose, and throat conditions: Clinical
Pediatric gastrointestinal bleeding: Clinical
Pediatric infectious rashes: Clinical
Pediatric lower airway conditions: Clinical
Pediatric ophthalmological conditions: Clinical
Pediatric orthopedic conditions: Clinical
Pediatric upper airway conditions: Clinical
Pediatric urological conditions: Clinical
Pediatric vomiting: Clinical
Adrenal masses and tumors: Clinical
Asthma: Clinical
Cystic fibrosis: Clinical
Diabetes mellitus: Clinical
Leukemia: Clinical
Lymphoma: Clinical
Pediatric allergies: Clinical
Pediatric bone tumors: Clinical
Seizures: Clinical
Sickle cell disease: Clinical
Chronic kidney disease: Clinical
Heart failure: Clinical
Hyperkalemia: Clinical
Hypernatremia: Clinical
Hypokalemia: Clinical
Hyponatremia: Clinical
Metabolic and respiratory acidosis: Clinical
Shock: Clinical
Mood disorders: Clinical
Congenital disorders: Clinical
Neonatal ICU conditions: Clinical
Neonatal jaundice: Clinical
Newborn management: Clinical
Perinatal infections: Clinical
Bleeding disorders: Clinical
Immunodeficiencies: Clinical
Brain tumors: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Toxidromes: Clinical
Vaccinations: Clinical

Transcript

Watch video only

Content Reviewers

Disability-adjusted life years or DALYs are a measurement of disease burden, which is the impact of a health problem on an individual or in a population.

Typically, disability-adjusted life years are used to compare the burden of two diseases, like type II diabetes - which is a chronic condition where the body doesn’t produce enough insulin - and malaria - which is an infectious disease spread by mosquitoes that causes a person to have flu-like symptoms.

These two diseases are usually hard to compare because they affect different populations, have different short-term and long-term complications, and are managed completely differently.

So, to compare the two diseases, you could calculate the disability-adjusted life years for both diabetes and malaria, and the disease with the highest disability-adjusted life years has the highest disease burden.

Disability-adjusted life years are particularly useful for helping determine how resources should be allocated to a specific health issue.

For example, if you have 100 thousand dollars to donate, do you want to spend it towards helping people with type II diabetes in Canada or helping people with malaria in India?

So let’s try to calculate the disability-adjusted life years for diabetes in Canada, and that requires knowing two things.

First, you need to know the years of life lost to premature death, or YLL.

The years of life lost is calculated by multiplying the number of deaths that were the result of the disease (N), and the standard life expectancy at the age of death (L).

The standard life expectancy is just the average life expectancy in a population minus the age of the person who died.

For example, the average life expectancy in Canada is 82 years old, so the standard life expectancy of a person at age 60 is 22 years, because 82 minus 60 is 22. And if we’re only talking about 1 person who died, the number of deaths is 1.

So the years of life lost for a 60-year-old person that died from diabetes would be 1 times 22, or 22 years.

Calculating the years of life lost for an entire population gets a little more complicated, since a population is usually made up of people in different age groups.

For example, let’s say you want to figure out the burden of diabetes in a population of 4,000 people randomly selected in Canada.

So, you recruit 1,000 individuals in each of the 4 different age categories - 0 to 19, 20 to 49, 50 to 79, and above 80 - and follow them for 10 years.

You find out that there was 1 death from diabetes in the youngest age group, then 3, 4, and 7 deaths in the older age groups.

You also find that the average age of death for each age group is 19, 40, 65, and 81, so you’re able to calculate the average life expectancy at the age of death using the average life expectancy in Canada - which is 82. So 82 minus 19 is 63; 82 minus 40 is 42; 82 minus 65 is 17; and 82 minus 81 is 1.

Finally, you can calculate the years of life lost in each age group by multiplying the number of deaths in each age group by the average life expectancy for each age group. So, 1 times 63 is 63; 3 times 42 is 126; 4 times 17 is 68; and 7 times 1 is 7.

When you add up all of the years of life lost in each age group, the total number of years of life lost is 264.

The second thing you need to calculate the disability-adjusted life years is the number of years lost due to disability, which is sometimes referred to as the years lived with disability, or YLD.

The years lost due to disability is calculated by multiplying the incidence rate of the disease - which is the number of new cases of the disease that occurred within a certain time period - the length or duration of disease - which is the average length of time a person had the disease before dying, and the disability weight - which is a number assigned to each disease that represents the severity of the disease, or how much a disease affects how a person lives their life.

Disability weights range between 0 and 1, and in general, diseases with a score of 0 don’t limit a person’s ability to participate in any recreational, educational, procreational, or occupational activities.

People with diseases that have disability weights of 0.2 to 0.6 tend to have limited ability in some or all of those activities, and people with diseases that have disability scores of 0.8 or above typically need assistance with some or most daily activities.

For example, let’s say the disability weight for diabetes is 0.5. To calculate the years lost due to disability for a person in Canada who was diagnosed with diabetes at age 50, lived with diabetes for 10 years, and died at age 60, you would multiply the incidence - which would just be 1 in this case - times the duration - or 10 years - times the disability weight - or 0.5, which equals 5 years.

To calculate the number of years lost due to disability in a population you have to add up each of the years lost due to disability for each age group.

For example, let’s say that in 0-19 age group, there were 2 new cases of diabetes in the ten years of follow-up, so the incidence rate is 2 cases per 10 years for the youngest age group, and 9, 30, and 18 for the other age groups.

To figure out the average duration, you’d have to add up the number of years each person had diabetes until they died or until they moved into another age group.

Key Takeaways

The Disability-Adjusted Life Year (DALY) and Quality-Adjusted Life Year (QALY) are measures of population health used to quantify the burden of disease and injury. A DALY is a measure of lost healthy life years, while a QALY is a measure of how many years of life are lived in good health. Both measures incorporate the severity and duration of illness or injury and the age at which it occurs. They can be used to compare different diseases or injuries, or to compare the burden of disease between different populations.